Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
Abstract
..
All quercetin studies
..
Meta analysis
..
Feedback
Home
←
next
study
→
previous
study
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis
 

Exploring the bioactive compounds of Feiduqing formula for the prevention and management of COVID-19 through network pharmacology and molecular docking

Qin et al., Medical Data Mining, doi:10.53388/MDM202407003, Nov 2023
Source
PDF
All
Studies
Meta
Analysis
https://c19early.org/qin2.html
Quercetin for COVID-19
26th treatment shown to reduce risk in July 2021, now with p = 0.002 from 12 studies.
Lower risk for ICU, hospitalization, recovery, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
5,700+ studies for 169 treatments. c19early.org
In Silico study of components of Feiduqing finding that quercetin, among other compounds, has significant binding affinity to PTGS2, HSP90AA1, SARS-CoV-2 Mpro, and ACE2, suggesting that quercetin may have therapeutic potential for COVID-19. PTGS2 (prostaglandin-endoperoxide synthase 2), also known as COX-2, is an enzyme involved in prostaglandin biosynthesis and inflammation and is a target for anti-inflammatory drugs. HSP90AA1 is a heat shock protein that helps fold and stabilize proteins and has been shown to be important for replication of some RNA viruses.
80 preclinical studies support the efficacy of quercetin for COVID-19:
48 In Silico studies1-48
26 In Vitro studies1-5,8,18,22,24,28,45,49-63
6 In Vivo animal studies8,22,56,59,64,65
In Silico studies predict inhibition of SARS-CoV-2, or minimization of side effects, with quercetin or metabolites via binding to the spikeA,5,6,12,13,25,27,28,30,33,41,42,44,45,66 (and specifically the receptor binding domainB,67), MproC,2,5,6,10,12,14,16,18,20,21,23,26,27,30,33,37,39-41,45-48,67, RNA-dependent RNA polymeraseD,4-6,12,35,67, PLproE,6,40,48, ACE2F,25,26,30,31,40,44, TMPRSS2G,25, nucleocapsidH,6, helicaseI,6,32,37, endoribonucleaseJ,42, NSP16/10K,9, cathepsin LL,29, Wnt-3M,25, FZDN,25, LRP6O,25, ezrinP,43, ADRPQ,41, NRP1R,44, EP300S,19, PTGS2T,26, HSP90AA1U,19,26, matrix metalloproteinase 9V,34, IL-6W,24,38, IL-10X,24, VEGFAY,38, and RELAZ,38 proteins, and inhibition of spike-ACE2 interactionAA,3. In Vitro studies demonstrate inhibition of the MproC,18,50,55,63 protein, and inhibition of spike-ACE2 interactionAA,51. In Vitro studies demonstrate efficacy in Calu-3AB,54, A549AC,24, HEK293-ACE2+AD,62, Huh-7AE,28, Caco-2AF,53, Vero E6AG,22,45,53, mTECAH,56, RAW264.7AI,56, and HLMECAJ,3 cells. Animal studies demonstrate efficacy in K18-hACE2 miceAK,59, db/db miceAL,56,65, BALB/c miceAM,64, and rats22. Quercetin reduced proinflammatory cytokines and protected lung and kidney tissue against LPS-induced damage in mice64, inhibits LPS-induced cytokine storm by modulating key inflammatory and antioxidant pathways in macrophages8, and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity58.
Important missing comments or errors? Let us know.
a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.
b. The receptor binding domain is a specific region of the spike protein that binds ACE2 and is a major target of neutralizing antibodies. Focusing on the precise binding site allows highly specific disruption of viral attachment with reduced potential for off-target effects.
c. The main protease or Mpro, also known as 3CLpro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting Mpro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.
d. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.
e. The papain-like protease (PLpro) has multiple functions including cleaving viral polyproteins and suppressing the host immune response by deubiquitination and deISGylation of host proteins. Inhibiting PLpro may block viral replication and help restore normal immune responses.
f. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.
g. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.
h. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.
i. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.
j. The endoribonuclease, also known as NendoU or nsp15, cleaves specific sequences in viral RNA which may help the virus evade detection by the host immune system. Inhibition may hinder the virus's ability to mask itself from the immune system, facilitating a stronger immune response.
k. The NSP16/10 complex consists of non-structural proteins 16 and 10, forming a 2'-O-methyltransferase that modifies the viral RNA cap structure. This modification helps the virus evade host immune detection by mimicking host mRNA, making NSP16/10 a promising antiviral target.
l. Cathepsin L is a host lysosomal cysteine protease that can prime the spike protein through an alternative pathway when TMPRSS2 is unavailable. Dual targeting of cathepsin L and TMPRSS2 may maximize disruption of alternative pathways for virus entry.
m. Wingless-related integration site (Wnt) ligand 3 is a host signaling molecule that activates the Wnt signaling pathway, which is important in development, cell growth, and tissue repair. Some studies suggest that SARS-CoV-2 infection may interfere with the Wnt signaling pathway, and that Wnt3a is involved in SARS-CoV-2 entry.
n. The frizzled (FZD) receptor is a host transmembrane receptor that binds Wnt ligands, initiating the Wnt signaling cascade. FZD serves as a co-receptor, along with ACE2, in some proposed mechanisms of SARS-CoV-2 infection. The virus may take advantage of this pathway as an alternative entry route.
o. Low-density lipoprotein receptor-related protein 6 is a cell surface co-receptor essential for Wnt signaling. LRP6 acts in tandem with FZD for signal transduction and has been discussed as a potential co-receptor for SARS-CoV-2 entry.
p. The ezrin protein links the cell membrane to the cytoskeleton (the cell's internal support structure) and plays a role in cell shape, movement, adhesion, and signaling. Drugs that occupy the same spot on ezrin where the viral spike protein would bind may hindering viral attachment, and drug binding could further stabilize ezrin, strengthening its potential natural capacity to impede viral fusion and entry.
q. The Adipocyte Differentiation-Related Protein (ADRP, also known as Perilipin 2 or PLIN2) is a lipid droplet protein regulating the storage and breakdown of fats in cells. SARS-CoV-2 may hijack the lipid handling machinery of host cells and ADRP may play a role in this process. Disrupting ADRP's interaction with the virus may hinder the virus's ability to use lipids for replication and assembly.
r. Neuropilin-1 (NRP1) is a cell surface receptor with roles in blood vessel development, nerve cell guidance, and immune responses. NRP1 may function as a co-receptor for SARS-CoV-2, facilitating viral entry into cells. Blocking NRP1 may disrupt an alternative route of viral entry.
s. EP300 (E1A Binding Protein P300) is a transcriptional coactivator involved in several cellular processes, including growth, differentiation, and apoptosis, through its acetyltransferase activity that modifies histones and non-histone proteins. EP300 facilitates viral entry into cells and upregulates inflammatory cytokine production.
t. Prostaglandin G/H synthase 2 (PTGS2, also known as COX-2) is an enzyme crucial for the production of inflammatory molecules called prostaglandins. PTGS2 plays a role in the inflammatory response that can become severe in COVID-19 and inhibitors (like some NSAIDs) may have benefits in dampening harmful inflammation, but note that prostaglandins have diverse physiological functions.
u. Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1) is a chaperone protein that helps other proteins fold correctly and maintains their stability. HSP90AA1 plays roles in cell signaling, survival, and immune responses. HSP90AA1 may interact with numerous viral proteins, but note that it has diverse physiological functions.
v. Matrix metalloproteinase 9 (MMP9), also called gelatinase B, is a zinc-dependent enzyme that breaks down collagen and other components of the extracellular matrix. MMP9 levels increase in severe COVID-19. Overactive MMP9 can damage lung tissue and worsen inflammation. Inhibition of MMP9 may prevent excessive tissue damage and help regulate the inflammatory response.
w. The interleukin-6 (IL-6) pro-inflammatory cytokine (signaling molecule) has a complex role in the immune response and may trigger and perpetuate inflammation. Elevated IL-6 levels are associated with severe COVID-19 cases and cytokine storm. Anti-IL-6 therapies may be beneficial in reducing excessive inflammation in severe COVID-19 cases.
x. The interleukin-10 (IL-10) anti-inflammatory cytokine helps regulate and dampen immune responses, preventing excessive inflammation. IL-10 levels can also be elevated in severe COVID-19. IL-10 could either help control harmful inflammation or potentially contribute to immune suppression.
y. Vascular Endothelial Growth Factor A (VEGFA) promotes the growth of new blood vessels (angiogenesis) and has roles in inflammation and immune responses. VEGFA may contribute to blood vessel leakiness and excessive inflammation associated with severe COVID-19.
z. RELA is a transcription factor subunit of NF-kB and is a key regulator of inflammation, driving pro-inflammatory gene expression. SARS-CoV-2 may hijack and modulate NF-kB pathways.
aa. The interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor is a primary method of viral entry, inhibiting this interaction can prevent the virus from attaching to and entering host cells, halting infection at an early stage.
ab. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.
ac. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.
ad. HEK293-ACE2+ is a human embryonic kidney cell line engineered for high ACE2 expression and SARS-CoV-2 susceptibility.
ae. Huh-7 cells were derived from a liver tumor (hepatoma).
af. Caco-2 cells come from a colorectal adenocarcinoma (cancer). They are valued for their ability to form a polarized cell layer with properties similar to the intestinal lining.
ag. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.
ah. mTEC is a mouse tubular epithelial cell line.
ai. RAW264.7 is a mouse macrophage cell line.
aj. HLMEC (Human Lung Microvascular Endothelial Cells) are primary endothelial cells derived from the lung microvasculature. They are used to study endothelial function, inflammation, and viral interactions, particularly in the context of lung infections such as SARS-CoV-2. HLMEC express ACE2 and are susceptible to SARS-CoV-2 infection, making them a relevant model for studying viral entry and endothelial responses in the lung.
ak. A mouse model expressing the human ACE2 receptor under the control of the K18 promoter.
al. A mouse model of obesity and severe insulin resistance leading to type 2 diabetes due to a mutation in the leptin receptor gene that impairs satiety signaling.
am. A mouse model commonly used in infectious disease and cancer research due to higher immune response and susceptibility to infection.
Qin et al., 11 Nov 2023, China, peer-reviewed, 8 authors. Contact: epuswei@gmail.com, 874643370@qq.com.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperQuercetinAll
Exploring the bioactive compounds of Feiduqing formula for the prevention and management of COVID-19 through network pharmacology and molecular docking
Shuang-Lin Qin, Hui Yao, Ting Huang, Hong-Fei Yang, Ting-Ting Ge, Jie-Qiong Wang, Wei-Wu Wang, Qing Min
Medical Data Mining, doi:10.53388/mdm202407003
Background: To explore the effective chemical constituents of Feiduqing formula for prevention and treatment of coronavirus disease 2019 . Methods: The compounds and action targets of twelve herbal medicines in Feiduqing formula were collected via Traditional Chinese Medicine Systems Pharmacology Database and Analytic Platform. The genes corresponding to the targets were queried through the UniProt database. The "herbal medicine-ingredient-target" network was established by Cytoscape software. The Gene Ontology function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis were performed by Database for Annotation, Visualization and Integrated Discovery. Molecular docking was used to analyze the binding force of core active compounds of Feiduqing formula with PTGS2, HSP90AA1, SARS-CoV-2 3CL hydrolase and angiotensin converting enzyme II (ACE2). Results: The "herbal medicine-ingredient-target" network included 434 nodes and 1948 edges, including 222 components such as quercetin, kaempferol, luteolin, etc. The key targets are PTGS2, HSP90AA1, PTGS1, ESR1, AR, NOS2, etc. Gene Ontology function enrichment analysis revealed 2530 items, including RNA polymerase II-specific, response to oxidative stress, transcription factor activity, etc. Kyoto Encyclopedia of Genes and Genomes pathway enrichment screened 169 signal pathways, including Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Hepatitis B, Hepatitis C, IL-17, TNF, etc. The results of molecular docking showed that quercetin, luteolin, β-sitosterol, stigmasterol and other core active compounds have a certain degree of affinity with PTGS2, HSP90AA1, SARS-CoV-2 3CL hydrolase and ACE2. Conclusion: The active compounds of Feiduqing formula may have a therapeutic effect on COVID-19 pneumonia through the action on PTGS2, HSP90AA1, SARS-CoV-2 3CL hydrolase and ACE2, and regulating many signaling pathways.
Competing interests The authors declare no conflicts of interest.
References
Ahmed, Ramakrishnan, Systems biological approach of molecular descriptors connectivity: optimal descriptors for oral bioavailability prediction, PLoS One, doi:10.1371/journal.pone.0040654
Ai, Wu, Qi, Study on the Mechanisms of Active Compounds in Traditional Chinese Medicine for the Treatment of Influenza Virus by Virtual Screening, Interdiscip Sci, doi:10.1007/s12539-018-0289-0
Bai, Qin, Zhao, Wang, Wang, Integrated innovation of Chinese and western medicine: Target-combined Holistic Treatment, Chin Sci Bull, doi:10.1360/TB-2021-0867
Chen, Wang, Lu, Uncovering potential anti-neuroinflammatory components of Modified Wuziyanzong Prescription through a target-directed molecular docking fingerprint strategy, J Pharm Biomed Anal, doi:10.1016/j.jpba.2018.05.001
Cui, Li, Guo, Traditional Chinese medicine for treatment of coronavirus disease 2019: a review, Tradit Chin Med, doi:10.53388/TMR20200222165
Han, Zhao, Shi, Application of integrated traditional Chinese and Western medicine in the treatment of novel coronavirus pneumonia, Chin Tradit Herb Drugs
Health, Of, Prc, New Diagnostic and treatment protocol for coronavirus pneumonia (trial version 9)
Hopkins, Network pharmacology: the next paradigm in drug discovery, Nat Chem Biol, doi:10.1038/nchembio.118
Hsin, Ghosh, Kitano, Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology, PLoS One, doi:10.1371/journal.pone.0083922
Huang, Sherman, Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nat Protoc, doi:10.1038/nprot.2008.211
Kim, Thiessen, Bolton, PubChem Substance and Compound databases, Nucleic Acids Res, doi:10.1093/nar/gkv951
Li, Wang, Guo, Li, Efficacy and safety of traditional Chinese medicine for the treatment of influenza A (H1N1): A meta-analysis, J Chin Med Assoc, doi:10.1016/j.jcma.2015.10.009
Niu, Wang, Xiao, Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking, China J Chin Mater Med, doi:10.19540/j.cnki.cjcmm.20200206.501
Ru, Li, Wang, TCMSP: a database of systems pharmacology for drug discovery from herbal medicines, J Cheminform, doi:10.1186/1758-2946-6-13
Su, Morris, Demchak, Bader, Biological Network Exploration with Cytoscape 3, Curr Protoc Bioinformatics, doi:10.1002/0471250953.bi0813s47
Sun, Sun, Yan, Li, Xin, Data mining and systematic pharmacology to reveal the mechanisms of traditional Chinese medicine in Mycoplasma pneumoniae pneumonia treatment, Biomed Pharmacother, doi:10.1016/j.biopha.2020.109900
Ursu, Rayan, Goldblum, Oprea, Understanding drug-likeness, WIREs Comput Mol Sci, doi:10.1002/wcms.52
Wang, Horby, Hayden, Gao, A novel coronavirus outbreak of global health concern, Lancet, doi:10.1016/S0140-6736(20)30185-9
Wang, Liu, Chen, The establishment of reference sequence for SARS-CoV-2 and variation analysis, J Med Virol, doi:10.1002/jmv.25762
Wang, Qu, To understand the etiology of new coronavirus pneumonia from the point of view of traditional Chinese medicine, J Pract Tradit Chin Internal Med, doi:10.13729/j.issn.1671-7813.Z20220328
Wei, Zhong, Sun, Proteomic and mechanistic study of Qingxuan Tongluo formula and curcumin in the treatment of Mycoplasma pneumoniae pneumonia, Biomed Pharmacother, doi:10.1016/j.biopha.2020.110998
Xie, Gao, Li, Research progress and application strategy on network pharmacology in Chinese materia medica, Chin Tradit Herb Drugs, doi:10.7501/j.issn.0253-2670.2019.10.001
Xing, Lyu, Chai, Zhu, Advances in the mechanism of traditional Chinese medicine by network pharma-cology method, J Pharm Pract, doi:10.3969/j.issn.1006-0111.2018.02.001
Yang, Cheng, Yan, A cell-based high-throughput protocol to screen entry inhibitors of highly pathogenic viruses with Traditional Chinese Medicines, J Med Virol, doi:10.1002/jmv.24705
Yang, Hu, Can Yin-Chai-Xiao-Du decoction be useful of COVID-19? The mechanism research based on network pharmacology, Tradit Chin Med, doi:10.53388/TMR20200601185
Yang, Li, Chao, Thinking on Etiology and pathogenesis of novel coronavirus pneumonia in traditional Chinese medicine, J Tradit Chin Med, doi:10.13288/j.11-2166/r.2020.07.002
Yang, Yt, Miao, Network pharmacology studies on the effect of Chai-Ling decoction in coronavirus disease, Tradit Med Res, doi:10.53388/TMR20200324170
Zhang, Cui, Zhang, Efficacy of Xuebijing injection for the treatment of coronavirus disease 2019 via network pharmacology, Tradit Chin Med, doi:10.53388/TMR20200507178
Zhang, Effect of integrated traditional Chinese and Western medicine on SARS: A review of clinical evidence, World J Gastroenterol, doi:10.3748/wjg.v10.i23.3500
DOI record: { "DOI": "10.53388/mdm202407003", "ISSN": [ "2624-1587" ], "URL": "http://dx.doi.org/10.53388/MDM202407003", "alternative-id": [ "MDM202407003" ], "author": [ { "affiliation": [], "family": "Qin", "given": "Shuang-Lin", "sequence": "first" }, { "affiliation": [], "family": "Yao", "given": "Hui", "sequence": "first" }, { "affiliation": [], "family": "Huang", "given": "Ting", "sequence": "additional" }, { "affiliation": [], "family": "Yang", "given": "Hong-Fei", "sequence": "additional" }, { "affiliation": [], "family": "Ge", "given": "Ting-Ting", "sequence": "additional" }, { "affiliation": [], "family": "Wang", "given": "Jie-Qiong", "sequence": "additional" }, { "affiliation": [], "family": "Wang", "given": "Wei-Wu", "sequence": "additional" }, { "affiliation": [], "family": "Min", "given": "Qing", "sequence": "additional" } ], "container-title": "Medical Data Mining", "container-title-short": "Med Data Min", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2023, 11, 3 ] ], "date-time": "2023-11-03T09:32:30Z", "timestamp": 1699003950000 }, "deposited": { "date-parts": [ [ 2023, 11, 3 ] ], "date-time": "2023-11-03T09:32:31Z", "timestamp": 1699003951000 }, "indexed": { "date-parts": [ [ 2023, 11, 4 ] ], "date-time": "2023-11-04T00:48:21Z", "timestamp": 1699058901940 }, "is-referenced-by-count": 0, "issue": "1", "issued": { "date-parts": [ [ 2024 ] ] }, "journal-issue": { "issue": "1", "published-print": { "date-parts": [ [ 2024 ] ] } }, "language": "en", "link": [ { "URL": "https://www.tmrjournals.com/public/articlePDF/20231103/52538735aa4515250ad7642ec908ad38.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "20794", "original-title": [], "page": "3", "prefix": "10.53388", "published": { "date-parts": [ [ 2024 ] ] }, "published-print": { "date-parts": [ [ 2024 ] ] }, "publisher": "TMR Publishing Group", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "https://www.tmrjournals.com/article.html?J_num=11&a_id=2954" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Process Chemistry and Technology", "Economic Geology", "Fuel Technology" ], "subtitle": [], "title": "Exploring the bioactive compounds of Feiduqing formula for the prevention and management of COVID-19 through network pharmacology and molecular docking", "type": "journal-article", "volume": "7" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0